Cost-utility of tofacitinib for the treatment of severe to moderate rheumatoid arthritis in Portugal

B. Pinheiro, M. Gouveia, M. Inês, M. Borges

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	PSY5
Pages (from-to)	S901-S901
Number of pages	1
Journal	Value in Health
Volume	22
Issue number	S3
Publication status	Published - Nov 2019
Event	ISPOR Europe 2019 - Bella Center Copenhagen, Copenhagen, Denmark Duration: 2 Jan 2019 → 6 Nov 2019

Cite this

@article{8f1dcf40975f4760b3d2b81a3f9132d1,

title = "Cost-utility of tofacitinib for the treatment of severe to moderate rheumatoid arthritis in Portugal",

author = "B. Pinheiro and M. Gouveia and M. In{\^e}s and M. Borges",

year = "2019",

month = nov,

language = "English",

volume = "22",

pages = "S901--S901",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Ltd.",

number = "S3",

note = "ISPOR Europe 2019 ; Conference date: 02-01-2019 Through 06-11-2019",

}

TY - JOUR

T1 - Cost-utility of tofacitinib for the treatment of severe to moderate rheumatoid arthritis in Portugal

AU - Pinheiro, B.

AU - Gouveia, M.

AU - Inês, M.

AU - Borges, M.

PY - 2019/11

Y1 - 2019/11

M3 - Meeting Abstract

SN - 1098-3015

VL - 22

SP - S901-S901

JO - Value in Health

JF - Value in Health

IS - S3

M1 - PSY5

T2 - ISPOR Europe 2019

Y2 - 2 January 2019 through 6 November 2019

ER -